M Holdings Securities Inc. Sells 177 Shares of Amgen Inc. (NASDAQ:AMGN)

M Holdings Securities Inc. decreased its holdings in Amgen Inc. (NASDAQ:AMGN – Get Rating) by 6.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,406 shares of the medical research company’s stock after selling 177 shares during the quarter. M Holdings Securities Inc.’s holdings in Amgen were worth $542,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of Amgen by 2.8% in the third quarter. Vanguard Group Inc. now owns 47,459,511 shares of the medical research company’s stock worth $10,697,373,000 after purchasing an additional 1,310,894 shares during the last quarter. FMR LLC grew its stake in shares of Amgen by 24.9% in the second quarter. FMR LLC now owns 8,911,384 shares of the medical research company’s stock worth $2,168,140,000 after purchasing an additional 1,774,223 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Amgen by 1.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 8,819,690 shares of the medical research company’s stock worth $2,132,778,000 after purchasing an additional 94,565 shares during the last quarter. Royal Bank of Canada grew its stake in shares of Amgen by 1.3% in the third quarter. Royal Bank of Canada now owns 6,097,683 shares of the medical research company’s stock worth $1,374,419,000 after purchasing an additional 75,721 shares during the last quarter. Finally, California Public Employees Retirement System grew its stake in shares of Amgen by 1.6% in the third quarter. California Public Employees Retirement System now owns 2,462,101 shares of the medical research company’s stock worth $554,958,000 after purchasing an additional 37,706 shares during the last quarter. Institutional investors own 75.53% of the company’s stock.

Amgen Trading Up 1.9 %

NASDAQ:AMGN opened at $234.90 on Thursday. The company has a debt-to-equity ratio of 10.20, a current ratio of 1.41 and a quick ratio of 1.10. The firm has a 50-day moving average of $247.46 and a 200-day moving average of $254.91. The company has a market cap of $125.43 billion, a PE ratio of 19.40, a PEG ratio of 1.84 and a beta of 0.65. Amgen Inc. has a one year low of $223.30 and a one year high of $296.67.

Amgen (NASDAQ:AMGN – Get Rating) last posted its earnings results on Tuesday, February 7th. The medical research company reported $4.09 EPS for the quarter, topping the consensus estimate of $4.04 by $0.05. The company had revenue of $6.84 billion during the quarter, compared to the consensus estimate of $6.77 billion. Amgen had a net margin of 24.89% and a return on equity of 359.47%. The firm’s revenue for the quarter was down .1% on a year-over-year basis. During the same period in the previous year, the firm posted $4.36 earnings per share. As a group, equities research analysts expect that Amgen Inc. will post 17.72 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 8th. Stockholders of record on Thursday, May 18th will be paid a $2.13 dividend. The ex-dividend date of this dividend is Wednesday, May 17th. This represents a $8.52 dividend on an annualized basis and a dividend yield of 3.63%. Amgen’s payout ratio is presently 70.36%.

Wall Street Analyst Weigh In

Several research firms recently issued reports on AMGN. Credit Suisse Group dropped their target price on shares of Amgen from $240.00 to $220.00 and set an “underperform” rating on the stock in a report on Wednesday, February 1st. Oppenheimer dropped their target price on shares of Amgen from $312.00 to $294.00 and set an “outperform” rating on the stock in a report on Wednesday, February 1st. Barclays dropped their target price on shares of Amgen from $240.00 to $230.00 and set an “underweight” rating on the stock in a report on Wednesday, February 1st. Piper Sandler dropped their target price on shares of Amgen from $299.00 to $293.00 and set an “overweight” rating on the stock in a report on Thursday, January 19th. Finally, Cowen dropped their target price on shares of Amgen from $307.00 to $289.00 and set an “outperform” rating on the stock in a report on Wednesday, February 1st. Four analysts have rated the stock with a sell rating, three have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $251.44.

Amgen Company Profile

(Get Rating)

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.